98%
921
2 minutes
20
Atopic dermatitis (AD) is a common chronic relapsing pruritic skin disease of dogs for which treatment has varied over time and geographical location. Recent high quality randomized controlled trials and systematic reviews have established which drugs are likely to offer consistent benefit. The International Task Force for Canine AD currently recommends a multi-faceted approach to treat dogs with AD. Acute flares should be treated with a combination of nonirritating baths and topical glucocorticoids, once an attempt has been made to identify and remove the suspected causes of the flare. Oral glucocorticoids and antimicrobial therapy must be added when needed. In dogs with chronic AD, a combination of interventions should be considered. Again, factors that trigger flares of AD must be identified and, if possible, avoided. Currently recognized flare factors include food, flea and environmental allergens, Staphylococcus bacteria and Malassezia yeast. Skin and coat hygiene and care must be improved by bathing with nonirritating shampoos and dietary supplementation with essential fatty acids. The severity of pruritus and skin lesions can be reduced with a combination of anti-inflammatory drugs. Currently, medications with good evidence of high efficacy include topical and oral glucocorticoids, and calcineurin inhibitors such as oral ciclosporin and topical tacrolimus. The dose and frequency of administration of these drugs should be tailored to each patient considering each drug's efficacy, adverse effects and cost. Allergen-specific immunotherapy should be offered, whenever feasible, in an attempt to prevent recurrence of clinical signs upon further exposure to environmental allergens to which the patient is hypersensitive.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-3164.2010.00889.x | DOI Listing |
Dermatitis
September 2025
From the Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
There are limited data regarding photopatch testing (PPT) in Israel. To investigate the prevalence of positive reactions and concurrent diagnosis of patients that underwent PPT in a single center in Israel. Retrospective cohort study that included all patients that were suspected of having contact dermatitis and underwent patch testing with the European baseline series (EBS) and additionally were selectively PPT with the Scandinavian/European baseline photopatch series in a tertiary medical center in Israel (2009-2023).
View Article and Find Full Text PDFDermatitis
September 2025
From the Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain.
Atopic dermatitis (AD) is a common chronic inflammatory skin condition influenced by genetic and environmental factors. The role of lifestyle on AD remains unclear. This study explores the association between adherence to the Mediterranean diet (MD), physical activity (PA) levels, and AD severity.
View Article and Find Full Text PDFJ Invest Dermatol
September 2025
Department of Dermatology, School of Medicine, University of California San Diego, San Diego, California, USA. Electronic address:
Int J Dermatol
July 2025
Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
J Dermatolog Treat
December 2025
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Objectives: The aim of this study is to evaluate the potential of online consultation services in a Swiss dermatological clinic as a tool for triage, focusing on time savings, patient satisfaction, and cost-effectiveness.
Methods: Over a period of 30 months, data were generated from a publicly available store-and-forward teledermatological platform (www.derma2go.